Quorum sensing inhibitors for pulmonary delivery as a novel treatment against Pseudomonas aeruginosa

• In: Short Communications B1 on Monday, 22 May 2017, 13:30-15:00
• At: Stockholm (Sweden) (2017)
• Type: Presentation
• By: SOU, Tomás (Uppsala University, Pharmacy, Uppsala, Sweden)
• Co-author(s): Tomás Sou: Department of Pharmacy, Uppsala University, Uppsala, Sweden
  Christel Bergström: Department of Pharmacy, Uppsala University, Uppsala, Sweden
  Miguel Cámara: School of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, United Kingdom
  Fadi Soukarieh: School of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, United Kingdom
  Michael Stocks: School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, United Kingdom
  Paul Williams: School of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, United Kingdom
  Irena Kukavica-Ibrulj: Institut de biologie intégrative et des systèmes, Université Laval, Québec, Canada
  Roger C. Levesque: Institut de biologie intégrative et des systèmes, Université Laval, Québec, Canada
  
• Abstract:

  Backgrounds

  Pseudomonas aeruginosa exhibits a high rate of resistance to many of the current therapies available. A novel class of anti-virulence agents, quorum sensing inhibitors (QSI), designed to suppress biofilm formation in P. aeruginosa, and therefore sensitise the bacteria to other antibiotic treatments, is currently being developed.

  Aims

  To

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login